Topic: mergers and acquisitions
It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.
Weeks after announcing a €5.32 billion ($5.63 billion) buyout, German generics maker Stada said the deal failed to get shareholder approval.
Switzerland-based CDMO Lonza said it has been given the green light by regulators for its $5.5 billion deal to buy U.S.-based contract capsule and drug producer Capsugel from KKR.
Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.
Albany-New York based AMRI has agreed to a buyout worth more than $920 million as the M&A market for contract manufacturers continues to run hot.
Valeant is in talks to sell its Bausch & Lomb eye surgery business to Carl Zeiss Meditec for potentially $2 billion, Bloomberg reports.
Sun's U.S. sales dropped 34% last quarter, Grail is merging with Hong Kong-based Cirina, Shanghai-based InventisBio raised $19 million in series B.
Thermo Fisher Scientific is acquiring Patheon—the center of the consolidation that has swept through contract manufacturing—in a deal valued at $7.2 billion.